A Detouring Experience Not Recommended: Lessons Learned from PF00299804.

Molly Li1,2, Kevin Mok3, Tony Mok1,2

  • 1Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong.

Cancer Research
|October 17, 2022
PubMed
Summary

Second-generation EGFR TKI PF00299804 demonstrated potent inhibition and ability to overcome T790M resistance mutations in preclinical models. This review examines its development and lessons learned for non-small cell lung cancer (NSCLC) treatment.